Trimel Pharmaceuticals (TRLPF) Lowered to Sell at ValuEngine

ValuEngine downgraded shares of Trimel Pharmaceuticals (OTCMKTS:TRLPF) from a hold rating to a sell rating in a research report released on Sunday.

Trimel Pharmaceuticals (OTCMKTS:TRLPF) remained flat at $$0.28 during mid-day trading on Friday. 2,637 shares of the company’s stock were exchanged, compared to its average volume of 36,791. The company has a quick ratio of 0.94, a current ratio of 1.81 and a debt-to-equity ratio of 0.20. Trimel Pharmaceuticals has a 52 week low of $0.08 and a 52 week high of $0.40.

COPYRIGHT VIOLATION NOTICE: “Trimel Pharmaceuticals (TRLPF) Lowered to Sell at ValuEngine” was first published by Week Herald and is owned by of Week Herald. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://weekherald.com/2017/12/04/trimel-pharmaceuticals-trlpf-lowered-to-sell-at-valuengine.html.

About Trimel Pharmaceuticals

Trimel Pharmaceuticals Corporation is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men’s health, women’s health and respiratory medicine. The Corporation holds a license for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system.

Receive News & Ratings for Trimel Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trimel Pharmaceuticals Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply